Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia in an Asymptomatic Genetically Positive Carrier

Finding a pathogenic mutation in a CPVT disease-causing gene in an individual who has never experienced ventricular arrhythmia and has no history of aborted cardiac arrest raises a specific clinical question: what management is appropriate before symptoms emerge?

Clinical Scenario

The patient is a confirmed carrier of a pathogenic mutation in a CPVT-linked gene but is currently asymptomatic — with no documented ventricular arrhythmia and no prior aborted cardiac arrest. This genotype-positive, phenotype-negative state is a recognised indication for structured, proactive management.

Approach Overview

The protocol addresses both lifestyle recommendations and pharmacological therapy for this population. The specific agents, their selection rationale, and the full management framework are detailed in the complete protocol — accessible below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehac262

It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.
This panel has confirmed the indication to treat genetically positive family members with beta-blockers, even in the absence of documented exercise- or stress-induced VAs.
Therapy with beta-blockers should be considered for genetically positive CPVT patients without phenotype.
Avoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with CPVT.
Non-selective beta-blockers such as nadolol and propranolol are preferred.

View source ↗